The surge in demand for COVID-19 vaccines has presented lucrative opportunities for both innovators and contract service providers having continuous and semi-continuous manufacturing capabilities for biointensification
Roots Analysis has announced the addition of “Continuous and Semi-Continuous Bioprocessing Market, 2021 – 2030” report to its list of offerings.
Given the growing pipeline of biological drugs, and the rising preference for such therapeutic interventions, the demand for cost-effective biomanufacturing processes has increased. As a result, several innovators and contract service providers are evaluating the potential of continuous and semi-continuous upstream and downstream bioprocessing technologies, owing to their various advantages.
To order this 190+ page report, which features 60+ figures and 115+ tables, please visit this link
Presently, more than 70 companies claim to have capabilities for continuous manufacturing of biologics
Close to 45% of the continuous and semi-continuous bioprocessing companies are headquartered in Europe; further, around 20% of these companies have established their dedicated facilities in other geographical regions, such as North America and Asia-Pacific.
Over 65% of the installed continuous upstream manufacturing capacity belongs to established players
More than 40% of the global continuous upstream processing capacity is installed in Europe, followed by Asia-Pacific (33%). Further, close to 55% of the capacity belongs to the facilities owned by contract service providers.
Continuous and semi-continuous bio-intensification approach has potential to save ~40% of the overall biopharmaceutical manufacturing cost
By 2030, we expect that adoption of continuous and semi-continuous approach is likely to enable the net, annual cost savings of close to USD 50 billion.
By 2030, the opportunity within the continuous and semi-continuous bioprocessing market is likely to be over USD 500 million
Presently, the use of continuous and semi-continuous bio-intensification approach is largely restricted to the developed nations, and the majority of revenues from biologics manufactured via this approach are distributed between North America (~25%) and Europe (~40%). Once this process is adopted for the end-to-end manufacturing of biologics, estimates in the report suggest are likely to grow at even higher pace.
To request a sample copy / brochure of this report, please visit this link
Key Questions Answered
The USD 500+ million (by 2030) financial opportunity associated with continuous and semi-continuous bioprocessing services market has been analyzed across the following segments:
The report also features inputs from eminent industry stakeholders, according to whom, continuous and semi-continuous bioprocessing technologies are likely to witness a significant increase in the adoption rate in the near future, given their advantages over the traditional bioprocessing technologies. The report includes detailed transcripts of discussions held with the following experts:
The research includes profiles of key players (listed below), featuring a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.
For additional details, please visit https://www.rootsanalysis.com/reports/continuous-and-semi-continuous-bioprocessing-market.html
or email sales@rootsanalysis.com
You may also be interested in the following titles:
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
MEDIA CITATIONS
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES
.png)
